[5-(4-hydroxy-phenyl)-3-methyl-isoxazol-4-yl]-carbamic acid (R)-1-(2-fluoro-phenyl)-ethyl ester | 1352803-40-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [5-(4-hydroxy-phenyl)-3-methyl-isoxazol-4-yl]-carbamic acid (R)-1-(2-fluoro-phenyl)-ethyl ester
• 英文别名: [(1R)-1-(2-fluorophenyl)ethyl] N-[5-(4-hydroxyphenyl)-3-methyl-1,2-oxazol-4-yl]carbamate
• CAS: 1352803-40-7
• 化学式: C₁₉H₁₇FN₂O₄
• 分子量: 356.353
• InChiKey: WEOPQCWGGKBHFU-GFCCVEGCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  84.6
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  [5-(4-hydroxy-phenyl)-3-methyl-isoxazol-4-yl]-carbamic acid (R)-1-(2-fluoro-phenyl)-ethyl ester 、 4-溴甲基苯甲酸甲酯 生成 4-(4-{4-[(R)-1-(2-Fluoro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-phenoxymethyl)-benzoic acid methyl ester
  参考文献：
  名称：

  ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS

  摘要：

  本文描述了一些抗溶血磷脂酸受体的化合物。还描述了包括上述化合物的药物组合物和药物，以及使用这些拮抗剂的方法，单独或与其他化合物结合，用于治疗依赖溶血磷脂酸或溶血磷脂酸介导的疾病或病症。

  公开号：

  US20110301142A1

文献信息

• LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CONDITIONS OR DISEASES OF THE EYE
  申请人：Hutchinson John Howard

  公开号：US20130253019A1

  公开（公告）日：2013-09-26

  Described herein is the use of LPA1 antagonists in the treatment or prevention of diseases or conditions of the eye of a mammal. Also described are pharmaceutical compositions that include at least one LPA1 antagonist.
• [EN] ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS D'ACIDE LYSOPHOSPHATIDIQUE
  申请人：AMIRA PHARMACEUTICALS INC

  公开号：WO2010077882A2

  公开（公告）日：2010-07-08

  Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.
• [EN] LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CONDITIONS OR DISEASES OF THE EYE<br/>[FR] ANTAGONISTES DE RÉCEPTEUR D'ACIDE LYSOPHOSPHATIDIQUE POUR LE TRAITEMENT D'AFFECTIONS OU MALADIES DE L'OEIL
  申请人：AMIRA PHARMACEUTICALS INC

  公开号：WO2011159632A1

  公开（公告）日：2011-12-22

  Described herein is the use of LPA1 antagonists in the treatment or prevention of diseases or conditions of the eye of a mammal. Also described are pharmaceutical compositions that include at least one LPA1 antagonist.
• [EN] LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST FOR THE TREATMENT OF DERMAL CONDITIONS<br/>[FR] ANTAGONISTE DE RÉCEPTEUR D'ACIDE LYSOPHOSPHATIDIQUE POUR LE TRAITEMENT D'AFFECTIONS DERMIQUES
  申请人：AMIRA PHARMACEUTICALS INC

  公开号：WO2011159635A1

  公开（公告）日：2011-12-22

  Described herein are LPA1 receptor antagonists, pharmaceutical compositions comprising at least one LPA1 receptor anatgonist, and methods of treating or preventing dermal diseases or conditions. Pharmaceutical compositions are suitable for systemic admistration or for topical administration.
• [EN] INHALABLE FORMULATIONS OF LYSOPHOSPHATDIC ACID RECEPTOR ANTAGONISTS<br/>[FR] FORMULATIONS INHALABLES D'ANTAGONISTES DE RÉCEPTEUR D'ACIDE LYSOPHOSPHATIDIQUE
  申请人：AMIRA PHARMACEUTICALS INC

  公开号：WO2011159633A1

  公开（公告）日：2011-12-22

  Described herein are inhalable pharmaceutical compositions comprising LPA receptor anatgonists wherein the pharmaceutical compositions facilitate delivery of LPA receptor antagonists to the lungs of a mammal. Also provided are methods of treating or preventing LPA-dependent or LPA-mediated diseases or conditions in a mammal by pulmonary administration of LPA receptor antagonists.